US5153312A
(en)
*
|
1990-09-28 |
1992-10-06 |
American Cyanamid Company |
Oligosaccharide conjugate vaccines
|
US7279162B1
(en)
|
1990-10-22 |
2007-10-09 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
|
US5622649A
(en)
*
|
1991-06-27 |
1997-04-22 |
Emory University |
Multiple emulsions and methods of preparation
|
FR2682388B1
(fr)
*
|
1991-10-10 |
1995-06-09 |
Pasteur Merieux Serums Vacc |
Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
|
DE69333107T2
(de)
*
|
1992-02-11 |
2004-01-29 |
Jackson H M Found Military Med |
Dualer träger für immunogene konstrukte
|
US7141244B1
(en)
*
|
1992-03-02 |
2006-11-28 |
Chiron Srl |
Helicobacter pylori proteins useful for vaccines and diagnostics
|
US5445817A
(en)
*
|
1992-08-21 |
1995-08-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
|
IL107026A0
(en)
*
|
1992-09-16 |
1993-12-28 |
Univ Tennessee Res Corp |
Antigen of hybrid m protein and carrier for group a streptococcal vaccine
|
US6531156B1
(en)
|
1994-04-15 |
2003-03-11 |
Temple University |
Aqueous solven encapsulation method, apparatus and microcapsules
|
GB2303855B
(en)
*
|
1994-07-01 |
1998-10-28 |
Rican Limited |
Helicobacter pylori antigenic protein preparation and immunoassays
|
US5565204A
(en)
*
|
1994-08-24 |
1996-10-15 |
American Cyanamid Company |
Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
|
AU725279B2
(en)
*
|
1995-06-07 |
2000-10-12 |
Alberta Research Council Inc. |
Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them
|
US5695768A
(en)
|
1995-06-07 |
1997-12-09 |
Alberta Research Council |
Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
|
US5866132A
(en)
*
|
1995-06-07 |
1999-02-02 |
Alberta Research Council |
Immunogenic oligosaccharide compositions
|
US6284884B1
(en)
|
1995-06-07 |
2001-09-04 |
North American Vaccine, Inc. |
Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
|
EP0833662B2
(en)
|
1995-06-23 |
2011-01-26 |
SmithKline Beecham Biologicals S.A. |
A vaccine composition comprsing a Haemophilus influenzae B polysaccharide conjugate antigen adsorbed onto aluminium phosphate
|
US6872398B2
(en)
*
|
1995-12-22 |
2005-03-29 |
The United States Of America As Represented By The Secretary Of The Army |
Conjugate vaccine against gram-negative bacterial infections
|
WO1997025429A1
(en)
|
1996-01-04 |
1997-07-17 |
Rican Limited |
Helicobacter pylori bacterioferritin
|
ZA97248B
(en)
*
|
1996-01-18 |
1997-07-18 |
Rohm & Haas |
Method for identifying and quantifying polymers utilizing immunoassay techniques
|
US6207157B1
(en)
|
1996-04-23 |
2001-03-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Conjugate vaccine for nontypeable Haemophilus influenzae
|
US6309646B1
(en)
|
1996-05-09 |
2001-10-30 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
|
ATE208629T1
(de)
*
|
1996-08-27 |
2001-11-15 |
Chiron Corp |
Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
|
US6299881B1
(en)
*
|
1997-03-24 |
2001-10-09 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
|
US6610293B1
(en)
*
|
1997-06-16 |
2003-08-26 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
|
US5847110A
(en)
*
|
1997-08-15 |
1998-12-08 |
Biomedical Frontiers, Inc. |
Method of reducing a schiff base
|
AU9597198A
(en)
|
1997-10-03 |
1999-04-27 |
Galenica Pharmaceuticals, Inc. |
Imine-forming polysaccharides, preparation thereof and the use thereof as adjuvants and immunostimulants
|
CA2320470A1
(en)
|
1998-02-05 |
1999-08-12 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
|
AU759391B2
(en)
*
|
1998-02-12 |
2003-04-10 |
Wyeth Holdings Corporation |
Pneumococcal and meningococcal vaccines formulated with interleukin-12
|
US7018637B2
(en)
*
|
1998-02-23 |
2006-03-28 |
Aventis Pasteur, Inc |
Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
|
AU760669B2
(en)
|
1998-04-28 |
2003-05-22 |
Galenica Pharmaceuticals, Inc. |
Polysaccharide-antigen conjugates
|
US7250494B2
(en)
*
|
1998-06-15 |
2007-07-31 |
Biosynexus Incorporated |
Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
|
US6858211B1
(en)
|
1998-07-20 |
2005-02-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vaccines against Escherichia coli O157 infection
|
NZ509986A
(en)
*
|
1998-08-19 |
2003-10-31 |
Baxter Healthcare S |
Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
|
US6797275B1
(en)
*
|
1998-12-04 |
2004-09-28 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
|
US6146902A
(en)
*
|
1998-12-29 |
2000-11-14 |
Aventis Pasteur, Inc. |
Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
|
GB9928196D0
(en)
*
|
1999-11-29 |
2000-01-26 |
Chiron Spa |
Combinations of B, C and other antigens
|
FR2806304B1
(fr)
*
|
2000-03-17 |
2002-05-10 |
Aventis Pasteur |
Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
|
US7749511B2
(en)
*
|
2000-04-18 |
2010-07-06 |
Endobiologics, Incorporated |
Anti-sepsis conjugate vaccine
|
JP2004515450A
(ja)
*
|
2000-04-18 |
2004-05-27 |
エンドバイオロジックス, インコーポレイテッド |
敗血症処置のためのリポ多糖結合体ワクチン
|
JP2004506086A
(ja)
*
|
2000-08-25 |
2004-02-26 |
アベンティス、パストゥール、リミテッド |
インフルエンザ菌感染症の予防用ワクチンとしてのインフルエンザ菌リポ多糖内部コアオリゴ糖エピトープ
|
US7723296B2
(en)
|
2001-01-18 |
2010-05-25 |
Genzyme Corporation |
Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
|
JP2005504718A
(ja)
|
2001-01-23 |
2005-02-17 |
アヴェンティス パストゥール |
多価髄膜炎菌多糖−タンパク質複合ワクチン
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
US20050175629A1
(en)
*
|
2001-08-31 |
2005-08-11 |
Giuseppe Del Giudice |
Helicobacter pylori vaccination
|
GB0129007D0
(en)
*
|
2001-12-04 |
2002-01-23 |
Chiron Spa |
Adjuvanted antigenic meningococcal compositions
|
CA2476626A1
(en)
*
|
2002-02-20 |
2003-08-28 |
Chiron Corporation |
Microparticles with adsorbed polypeptide-containing molecules
|
DE60325696D1
(de)
*
|
2002-02-22 |
2009-02-26 |
Ca Nat Research Council |
Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs
|
WO2003094961A1
(en)
*
|
2002-05-09 |
2003-11-20 |
Massimo Porro |
Improved polysaccharide and glycoconjugate vaccines_____________
|
DE60328481D1
(de)
|
2002-05-14 |
2009-09-03 |
Novartis Vaccines & Diagnostic |
Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
|
GB0211118D0
(en)
*
|
2002-05-15 |
2002-06-26 |
Polonelli Luciano |
Vaccines
|
KR101239242B1
(ko)
|
2002-08-02 |
2013-03-11 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
항원 조합물을 포함하는 나이세리아 백신 조성물
|
AU2003274511B2
(en)
|
2002-10-11 |
2009-06-04 |
Glaxosmithkline Biologicals S.A. |
Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
|
US8409587B2
(en)
|
2002-11-01 |
2013-04-02 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
US8034378B2
(en)
|
2002-12-27 |
2011-10-11 |
Novartis Vaccines And Diagnostics, Inc |
Immunogenic compositions containing phospholipid
|
FR2850106B1
(fr)
|
2003-01-17 |
2005-02-25 |
Aventis Pasteur |
Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
|
CN102302776B
(zh)
|
2003-01-30 |
2014-06-18 |
诺华疫苗和诊断有限公司 |
抗多种脑膜炎球菌血清组的可注射性疫苗
|
US7893096B2
(en)
|
2003-03-28 |
2011-02-22 |
Novartis Vaccines And Diagnostics, Inc. |
Use of small molecule compounds for immunopotentiation
|
EP2301571A1
(en)
|
2003-05-07 |
2011-03-30 |
Sanofi Pasteur Inc. |
Tetravalent meningococcal vaccine with enhanced immunogenicity
|
BRPI0410341B8
(pt)
|
2003-05-07 |
2021-05-25 |
Sanofi Pasteur Inc |
conjugados de polissacarídeo-proteína derivatizados de meningococos multivalentes e vacina
|
PT1631264E
(pt)
|
2003-06-02 |
2009-11-03 |
Novartis Vaccines & Diagnostic |
Composições imunogénicas à base de micropartículas biodegradáveis que compreendem um toxóide de difteria e do tétano
|
GB0313916D0
(en)
|
2003-06-16 |
2003-07-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
US20070020293A1
(en)
*
|
2003-06-23 |
2007-01-25 |
Michon Francis J |
Vaccines against group neisseria meningitidis and meningococcal combinations thereof
|
MXPA05014171A
(es)
|
2003-06-23 |
2007-02-21 |
Sanofi Pasteur Inc |
Metodo de inmunizacion contra neisseria meningitidis serogrupos a y c.
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
BRPI0415025A
(pt)
|
2003-10-02 |
2006-12-12 |
Chiron Srl |
vacinas lìquidas para sorogrupos meningocócicos múltiplos
|
EP1667712B1
(en)
|
2003-10-02 |
2010-07-21 |
GlaxoSmithKline Biologicals S.A. |
B. pertussis antigens and use thereof in vaccination
|
EA012984B1
(ru)
|
2003-12-17 |
2010-02-26 |
Вайет |
Конъюгаты иммуногенных пептидных носителей и способы их получения
|
MY144231A
(en)
|
2003-12-17 |
2011-08-15 |
Wyeth Corp |
Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
|
US7422755B2
(en)
*
|
2004-01-15 |
2008-09-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Antimultiorganism glycoconjugate vaccine
|
WO2005072778A2
(en)
*
|
2004-01-29 |
2005-08-11 |
Biosynexus, Inc. |
Use of amino-oxy functional groups in the preparation of vaccines conjugates
|
GB0406013D0
(en)
|
2004-03-17 |
2004-04-21 |
Chiron Srl |
Analysis of saccharide vaccines without interference
|
GB0408978D0
(en)
|
2004-04-22 |
2004-05-26 |
Chiron Srl |
Meningococcal fermentation for preparing conjugate vaccines
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
RU2379052C2
(ru)
|
2004-04-30 |
2010-01-20 |
Чирон С.Р.Л. |
Вакцинация менингококковыми конъюгатами
|
GB0411387D0
(en)
|
2004-05-21 |
2004-06-23 |
Chiron Srl |
Analysis of saccharide length
|
GB0413868D0
(en)
|
2004-06-21 |
2004-07-21 |
Chiron Srl |
Dimensional anlaysis of saccharide conjugates
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
JP2008508320A
(ja)
|
2004-07-29 |
2008-03-21 |
カイロン コーポレイション |
Streptococcusagalactiaeのようなグラム陽性細菌に対する免疫原性組成物
|
BRPI0515125A
(pt)
|
2004-08-30 |
2008-07-08 |
Sanofi Pasteur Inc |
conjugados de polissacarìdeo derivatizado-proteìna multivalentes, meningocócicos e vacina
|
GB0420466D0
(en)
*
|
2004-09-14 |
2004-10-20 |
Cassone Antonio |
Anti-glucan antibodies
|
EP1791562A4
(en)
|
2004-09-21 |
2008-07-09 |
Sanofi Pasteur Inc |
ADDITIONAL POLYACOCARPHARATE-PROTEIN CONJUGATES AND VACCINES FROM MENINGOCOCKS
|
US9084809B2
(en)
*
|
2005-09-21 |
2015-07-21 |
The United States Of America As Represented By The Secretary Of The Navy |
Immunogenic capsule composition for use as a vaccine component against Campylobacter jejuni
|
GB0502096D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Purification of streptococcal capsular polysaccharide
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0505518D0
(en)
|
2005-03-17 |
2005-04-27 |
Chiron Srl |
Combination vaccines with whole cell pertussis antigen
|
GB0505996D0
(en)
|
2005-03-23 |
2005-04-27 |
Glaxosmithkline Biolog Sa |
Fermentation process
|
US20070184072A1
(en)
*
|
2005-04-08 |
2007-08-09 |
Wyeth |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
US7709001B2
(en)
*
|
2005-04-08 |
2010-05-04 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
US7955605B2
(en)
|
2005-04-08 |
2011-06-07 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
AU2011253684B8
(en)
*
|
2005-04-08 |
2013-07-11 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
IL308456A
(en)
|
2005-04-08 |
2024-01-01 |
Wyeth Llc |
A multivalent pneumomuroral protein-polysaccharide conjugate preparation
|
US8329184B2
(en)
|
2005-06-27 |
2012-12-11 |
Glaxosmithkline Biologicals S.A. |
Process for manufacturing vaccines
|
CA2621023C
(en)
|
2005-09-01 |
2019-07-02 |
Novartis Vaccines And Diagnostics Gmbh & Co. Kg |
Multiple vaccination including serogroup c meningococcus
|
US9999591B2
(en)
*
|
2005-09-21 |
2018-06-19 |
The United States Of America As Represented By The Secretary Of The Navy |
Immunogenic composition against Campylobacter jejuni
|
US7700578B2
(en)
*
|
2005-09-21 |
2010-04-20 |
The United States Of America As Represented By The Secretary Of The Navy |
Capsule composition for use as immunogen against Campylobacter jejuni
|
GB0522303D0
(en)
|
2005-11-01 |
2005-12-07 |
Chiron Srl |
Culture method
|
CA2630220C
(en)
|
2005-11-22 |
2020-10-13 |
Doris Coit |
Norovirus and sapovirus antigens
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
PT1962899E
(pt)
|
2005-12-22 |
2011-10-19 |
Glaxosmithkline Biolog Sa |
Vacina conjugada polissacarídica pneumocócica
|
JP4822854B2
(ja)
*
|
2006-01-18 |
2011-11-24 |
株式会社有沢製作所 |
フレキシブルプリント配線板用ポリアミドイミド樹脂、並びに該樹脂を用いた金属張り積層板、カバーレイ、フレキシブルプリント配線板、及び樹脂組成物
|
WO2007111940A2
(en)
|
2006-03-22 |
2007-10-04 |
Novartis Ag |
Regimens for immunisation with meningococcal conjugates
|
GB0605757D0
(en)
|
2006-03-22 |
2006-05-03 |
Chiron Srl |
Separation of conjugated and unconjugated components
|
EP2010537B1
(en)
|
2006-03-23 |
2011-12-28 |
Novartis AG |
Imidazoquinoxaline compounds as immunomodulators
|
CA2646891A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
WO2007109810A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Methods for the preparation of imidazole-containing compounds
|
US8808707B1
(en)
|
2006-05-08 |
2014-08-19 |
Wyeth Llc |
Pneumococcal dosing regimen
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
ZA200900899B
(en)
*
|
2006-08-07 |
2010-07-28 |
Harvard College |
Protein matrix vaccines and methods of making and administering such vaccines
|
MX2009001412A
(es)
|
2006-08-07 |
2009-04-24 |
Harvard College |
Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
|
EA016417B1
(ru)
|
2006-09-07 |
2012-04-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Способ получения вакцины
|
GB0700136D0
(en)
|
2007-01-04 |
2007-02-14 |
Glaxosmithkline Biolog Sa |
Process for manufacturing vaccines
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
DK2457920T3
(en)
|
2007-01-18 |
2018-01-22 |
Genzyme Corp |
Oligosaccharides comprising an amino oxy group and conjugates thereof
|
AR066376A1
(es)
|
2007-05-02 |
2009-08-12 |
Glaxosmithkline Biolog Sa |
Vacuna
|
AU2008259423A1
(en)
|
2007-06-04 |
2008-12-11 |
Novartis Ag |
Formulation of meningitis vaccines
|
BRPI0813644B8
(pt)
|
2007-06-26 |
2021-05-25 |
Glaxosmithkline Biologicals Sa |
composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
|
CN101969992B
(zh)
|
2007-09-12 |
2014-10-01 |
诺华股份有限公司 |
Gas57突变型抗原和gas57抗体
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
NZ586430A
(en)
|
2007-12-21 |
2012-09-28 |
Novartis Ag |
Mutant forms of streptolysin o (slo)
|
EP2349520B1
(en)
|
2008-10-27 |
2016-05-25 |
GlaxoSmithKline Biologicals SA |
Purification method for carbohydrate from group a streptococcus
|
GB0822633D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Formulation
|
SI2889043T1
(sl)
|
2008-12-16 |
2019-08-30 |
Genzyme Corporation |
Sintetične vmesne spojine za pripravo konjugatov oligosaharid-protein
|
CN102481349B
(zh)
|
2009-01-12 |
2014-10-15 |
诺华股份有限公司 |
抗革兰氏阳性细菌疫苗中的Cna_B结构域
|
WO2010083477A2
(en)
|
2009-01-16 |
2010-07-22 |
University Of Maryland, Baltimore |
Broad spectrum vaccine against non-typhoidal salmonella
|
US20120135037A1
(en)
|
2009-06-01 |
2012-05-31 |
Mizel Steven B |
Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
|
WO2011017101A2
(en)
|
2009-07-27 |
2011-02-10 |
Fina Biosolutions, Llc |
Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
|
AU2010352695B2
(en)
|
2009-09-30 |
2014-08-21 |
Glaxosmithkline Biologicals S.A. |
Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
GB0917647D0
(en)
|
2009-10-08 |
2009-11-25 |
Glaxosmithkline Biolog Sa |
Expression system
|
BR122019005883A8
(pt)
|
2009-10-30 |
2022-10-04 |
Novartis Ag |
Método para liberação de polissacarídeo capsular, processo de purificação de sacarídeos capsulares tipo 5 e tipo 8 de staphylococcus aureus e composição
|
MX2012006961A
(es)
|
2009-12-17 |
2012-10-03 |
Fina Biosolutions Llc |
Reactivos quimicos para la activacion de polisacaridos en la preparacion de vacunas conjugadas.
|
US9173954B2
(en)
|
2009-12-30 |
2015-11-03 |
Glaxosmithkline Biologicals Sa |
Polysaccharide immunogens conjugated to E. coli carrier proteins
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
CA2792683A1
(en)
|
2010-03-10 |
2011-09-15 |
Glaxosmithkline Biologicals S.A. |
Neisserial fhbp vaccine composition
|
WO2012020326A1
(en)
|
2010-03-18 |
2012-02-16 |
Novartis Ag |
Adjuvanted vaccines for serogroup b meningococcus
|
EP2556151A1
(en)
|
2010-04-07 |
2013-02-13 |
Novartis AG |
Method for generating a parvovirus b19 virus-like particle
|
US8383783B2
(en)
|
2010-04-23 |
2013-02-26 |
Serum Institute Of India, Ltd. |
Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
|
WO2011133227A2
(en)
|
2010-04-23 |
2011-10-27 |
Ancora Pharmaceuticals Inc. |
Synthetic oligosaccharides for staphyloccocus vaccine
|
WO2011137181A1
(en)
|
2010-04-27 |
2011-11-03 |
Ancora Pharmaceuticals Inc. |
Synthetic oligosaccharides for moraxella vaccine
|
WO2011149778A1
(en)
|
2010-05-26 |
2011-12-01 |
Ancora Pharmaceuticals Inc. |
Synthetic oligosaccharides for neisseria meningitis vaccine
|
WO2011149564A1
(en)
|
2010-05-28 |
2011-12-01 |
Tetris Online, Inc. |
Interactive hybrid asynchronous computer game infrastructure
|
EP2591097A1
(en)
|
2010-07-06 |
2013-05-15 |
Novartis AG |
Norovirus derived immunogenic compositions and methods
|
GB201015132D0
(en)
|
2010-09-10 |
2010-10-27 |
Univ Bristol |
Vaccine composition
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
CA2860331A1
(en)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Compounds
|
CN102068690A
(zh)
*
|
2010-12-31 |
2011-05-25 |
北京民海生物科技有限公司 |
多价肺炎球菌荚膜多糖结合疫苗及其制备方法
|
RU2013144207A
(ru)
|
2011-03-02 |
2015-04-10 |
Новартис Аг |
Комбинированные вакцины с пониженными дозами антигена и/или адъюванта
|
US9273210B2
(en)
|
2011-03-29 |
2016-03-01 |
Covestro Deutschland Ag |
Use of an aqueous preparation for the coating of wood surfaces to achieve a natural-touch effect
|
WO2012130764A1
(en)
|
2011-03-29 |
2012-10-04 |
Bayer Materialscience Ag |
Use of an aqueous preparation for the coating of wood surfaces to achieve a natural-touch effect
|
GB201106225D0
(en)
|
2011-04-13 |
2011-05-25 |
Glaxosmithkline Biolog Sa |
Fermentation process
|
US9149541B2
(en)
|
2011-07-08 |
2015-10-06 |
Novartis Ag |
Tyrosine ligation process
|
EP2736921B1
(en)
|
2011-07-25 |
2018-06-27 |
GlaxoSmithKline Biologicals SA |
Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
|
CN103917245B
(zh)
*
|
2011-09-14 |
2017-06-06 |
葛兰素史密丝克莱恩生物有限公司 |
用于制备糖‑蛋白质糖缀合物的方法
|
CN104080479B
(zh)
|
2011-11-07 |
2019-11-05 |
葛兰素史密丝克莱恩生物有限公司 |
包括spr0096和spr2021抗原的运载体分子
|
GB2495341B
(en)
|
2011-11-11 |
2013-09-18 |
Novartis Ag |
Fermentation methods and their products
|
DE102011118371B4
(de)
|
2011-11-11 |
2014-02-13 |
Novartis Ag |
Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
|
DE102011122891B4
(de)
|
2011-11-11 |
2014-12-24 |
Novartis Ag |
Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
|
EP2592137A1
(en)
|
2011-11-11 |
2013-05-15 |
Novartis AG |
Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
JP2015509963A
(ja)
|
2012-03-08 |
2015-04-02 |
ノバルティス アーゲー |
Tlr4アゴニストを含む混合ワクチン
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
ES2820898T3
(es)
|
2012-05-22 |
2021-04-22 |
Glaxosmithkline Biologicals Sa |
Conjugado del serogrupo X de meningococos
|
KR102057217B1
(ko)
|
2012-06-20 |
2020-01-22 |
에스케이바이오사이언스 주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
JP6324961B2
(ja)
|
2012-09-06 |
2018-05-16 |
ノバルティス アーゲー |
血清群b髄膜炎菌とd/t/pとの組み合わせワクチン
|
US20160101187A1
(en)
|
2012-10-02 |
2016-04-14 |
Novartis Ag |
Nonlinear saccharide conjugates
|
CN104582718B
(zh)
|
2012-10-03 |
2017-10-24 |
诺华股份有限公司 |
免疫原性组合物
|
CA2886938A1
(en)
|
2012-10-12 |
2014-04-17 |
Glaxosmithkline Biologicals S.A. |
Non-cross-linked acellular pertussis antigens for use in combination vaccines
|
KR20140075196A
(ko)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
EP2743695A1
(en)
|
2012-12-12 |
2014-06-18 |
Nanogap Sub NM Powder, S.A. |
Methods and reagents for the detection of biomolecules using luminescence
|
WO2014095771A1
(en)
|
2012-12-18 |
2014-06-26 |
Novartis Ag |
Conjugates for protecting against diphtheria and/or tetanus
|
IL274500B2
(en)
*
|
2012-12-20 |
2024-01-01 |
Pfizer |
glycoconjugation process
|
ITMI20130142A1
(it)
*
|
2013-01-31 |
2014-08-01 |
Biosynth Srl |
Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
|
WO2014135651A1
(en)
|
2013-03-08 |
2014-09-12 |
Crucell Holland B.V. |
Acellular pertussis vaccine
|
CN105492454B
(zh)
*
|
2013-07-07 |
2019-09-27 |
马普科技促进协会 |
合成针对1型肺炎链球菌的疫苗
|
AU2014286990A1
(en)
|
2013-07-11 |
2016-02-11 |
Novartis Ag |
Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
|
US9822150B2
(en)
|
2013-09-08 |
2017-11-21 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
PT3096786T
(pt)
*
|
2014-01-21 |
2021-08-24 |
Pfizer |
Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos
|
EP3193918A4
(en)
|
2014-09-18 |
2018-06-20 |
University of Maryland, Baltimore |
Broad spectrum conjugate vaccine to prevent klebsiella pneumoniae and pseudomonas aeruginosa infections
|
US9107906B1
(en)
|
2014-10-28 |
2015-08-18 |
Adma Biologics, Inc. |
Compositions and methods for the treatment of immunodeficiency
|
JP2017537145A
(ja)
|
2014-11-05 |
2017-12-14 |
ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーThe United States Of America As Represented By The Secretary Of The Navy |
カンピロバクター・ジェジュニに対する合成抗原コンストラクト
|
US10500261B2
(en)
|
2014-11-05 |
2019-12-10 |
The United States Of America As Represented By The Secretary Of The Navy |
Synthetic antigen constructs against campylobacter jejuni
|
EP3034516A1
(en)
|
2014-12-19 |
2016-06-22 |
Novartis AG |
Purification of streptococcal capsular polysaccharide
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP3377098A1
(en)
*
|
2015-11-20 |
2018-09-26 |
Pfizer Inc |
Immunogenic compositions for use in pneumococcal vaccines
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
EP3474890A1
(en)
|
2016-06-22 |
2019-05-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. |
Pneumococcal polysaccharide-protein conjugate composition
|
EP3269385A1
(en)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
WO2018074296A1
(ja)
|
2016-10-20 |
2018-04-26 |
一般財団法人化学及血清療法研究所 |
低分子化PRPを用いたHibコンジュゲートワクチンの製造方法
|
BE1025162B9
(fr)
|
2016-12-06 |
2019-01-07 |
Glaxosmithkline Biologicals Sa |
Procede de purification pour les polysaccharides capsulaires
|
PE20191107A1
(es)
|
2017-01-31 |
2019-08-26 |
Pfizer |
Composiciones de neisseria meningitidis y metodos respectivos
|
CN116870144A
(zh)
|
2017-01-31 |
2023-10-13 |
默沙东有限责任公司 |
制备多糖-蛋白缀合物的方法
|
US10259865B2
(en)
|
2017-03-15 |
2019-04-16 |
Adma Biologics, Inc. |
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
|
JP6950099B2
(ja)
|
2018-02-05 |
2021-10-13 |
サノフィ パスツール インコーポレイティッド |
多価肺炎球菌多糖体−タンパク質複合体組成物
|
EP3782642A4
(en)
*
|
2018-04-18 |
2022-04-13 |
SK Bioscience Co., Ltd. |
CAPSULE POLYSACCHARIDES FROM STREPTOCOCCUS PNEUMONIAE AND CONJUGATES THEREOF
|
BR112021000529A2
(pt)
|
2018-07-19 |
2021-04-06 |
Glaxosmithkline Biologicals S.A. |
Processos para preparar polissacarídeos secos
|
WO2020043874A1
(en)
|
2018-08-31 |
2020-03-05 |
Glaxosmithkline Biologicals Sa |
Conjugated haemophilus influenzae vaccine using bordetella outer membrane vesicle
|
CN113227125A
(zh)
|
2018-12-12 |
2021-08-06 |
葛兰素史密丝克莱恩生物有限公司 |
用于o-连接的糖基化的修饰的载体蛋白
|
CA3129425A1
(en)
|
2019-02-11 |
2020-08-20 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
EP3757217A1
(en)
|
2019-06-27 |
2020-12-30 |
GlaxoSmithKline Biologicals S.A. |
Methods for protein purification
|
EP3777884A1
(en)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic composition
|
BR112022004921A2
(pt)
|
2019-09-27 |
2022-07-19 |
Pfizer |
Composições para neisseria meningitidis e métodos das mesmas
|
EP3799884A1
(en)
|
2019-10-01 |
2021-04-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
EP3900739A1
(en)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
|
EP3919076A1
(en)
|
2020-06-02 |
2021-12-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
|
WO2021250628A1
(en)
|
2020-06-12 |
2021-12-16 |
Glaxosmithkline Biologicals Sa |
Bacterial immunization using nanoparticle vaccine
|
CA3185639A1
(en)
|
2020-06-25 |
2021-12-30 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
EP4243862A1
(en)
|
2020-11-13 |
2023-09-20 |
GlaxoSmithKline Biologicals SA |
Bacterial protein carriers and conjugation methods
|
WO2023111826A1
(en)
|
2021-12-14 |
2023-06-22 |
Glaxosmithkline Biologicals Sa |
Bacterial immunization using qbeta hairpin nanoparticle constructs
|
WO2023200704A1
(en)
|
2022-04-11 |
2023-10-19 |
Sanofi Pasteur Inc. |
Protein-saccharide conjugation with sodium cyanoborohydride
|
GB202215414D0
(en)
|
2022-10-18 |
2022-11-30 |
Glaxosmithkline Biologicals Sa |
Vaccine
|